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Each CYP2A6 gene variant metabolizes nicotine differently depending on its enzymatic activities.The normal nicotine metabolizer
CYP2A6*1A is associated with high scores of nicotine dependence (5–10) on the Fagerstro¨m Test for Nicotine Dependence
(FTND) scale because it encodes for enzymes that catalyze nicotine 100%. Slow nicotine metabolizers (i.e., CYP2A6*1H,
CYP2A6*4A, CYP2A6*9, and CYP2A6*12A) are associated with underrated nicotine metabolizing activity (50%–75%), linking
them to low scores for nicotine dependence (0–4) on the FTND scale. In a clinical trial involving the use of bupropion,
people who were carriers of slow nicotine metabolizers were found to have a tendency to maintain abstinence 1.7 times
longer than people with normal nicotine metabolizers. An overview of CYP2A6 polymorphism enzymatic activities in nicotine
dependence etiology and treatment revealed that slow nicotine metabolizers may strengthen the individualized treatment of
nicotine dependence.
1. Introduction
CYP2A6 polymorphism consists of alleleswith variable struc-
tures, ranging from deleted alleles (CYP2A6*2A/CYP2*4A) to
fully functioning alleles (CYP2A6*1A), which determine the
role that their level of enzymatic activity plays in nicotine
etiology and the impact they have on nicotine dependence
treatment [1, 2].The nicotine candidate gene CYP2A6*1A has
normally high enzymatic activity in nicotine digestion and
is responsible, in part, for the high prevalence of smoking
by predisposing people to nicotine addiction [3, 4], causing
more than 5 million [5, 6] smoking-related deaths and
disabilities each year. On the other hand, slow nicotine
metabolizers may realize potential clinical benefits since they
metabolize less nicotine [1]. This paper reviews the ability of
CYP2A6 polymorphisms to digest nicotine differentially and
investigates their impact on nicotine dependency treatment
in the context of personalized treatments for nicotine depen-
dence.
2. Study Background and
Theoretical Foundation
The enzymatic activities of the normal nicotine metabolizer
CYP2A6*1A can be considered to be responsible, in part,
for the high prevalence of nicotine dependence due to
CYP2A6*1A’s excessive metabolism of inhaled nicotine [1].
The slow nicotine metabolizer alleles of CYP2A6 catalyze less
nicotine and positively influence nicotine-dependence treat-
ment [7]. Nevertheless, current pharmacotherapy treatments
are not tailored to the genetic makeup of nicotine-dependent
people, limiting the odds of successful treatment outcomes
in nicotine dependence. Unfortunately, more than 5 million
deaths annually are linked to tobacco-related diseases. In the
United States (US) alone, the smoking prevalence is still 20%;
moreover, approximately 400,000 deaths each year are associ-
ated with tobacco-related diseases [5, 6], thereby compelling
a search for a novel treatment for nicotine dependence.
In general, the implication of genes in addiction etiology
and their possible use in treatment should be considered to
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Figure 1: Factors influencing nicotine behavior and metabolism rate. Note. Environmental, cultural, and social factors may influence the
development of nicotine intake, but nicotine metabolism is best modulated by CYP2A6 genes which release cotinine into blood to reach
brain inducing pleasurable feeling for smokers.
individualize addiction treatment. Behavioral Genetic The-
ory (BGT) underlines the existence of a correlation between
genes and addresses the role that exposure to environ-
mental agents [8–12] plays in an individual’s predisposition
to develop an addiction or in preventing an individual
from becoming addicted to a substance. For example, the
interaction between nicotine and theCYP2A6 polymorphism
CYP2A6*1A (normal nicotine metabolizer) leads to nicotine
addiction [13].
The capability of genes to metabolize drugs can
strengthen or weaken nicotine dependence treatment by in-
fluencing nicotine pharmacodynamics and pharmacokinet-
ics [5, 14]. Nicotine is an environmental agent; when it
interacts with specific candidate nicotine genes, it can play an
important role in the development of nicotine dependence
[14], as shown in Figure 1. The normal nicotine metabolizer
CYP2A6*1A is one of the first biological mediators of
nicotine digestion [15]. The suppression or alteration of the
CYP2A6*1A gene variant, which excessively metabolizes
nicotine, should lead to the excretion of undigested nicotine
in the urine by blocking cotinine from reaching the brain,
thereby slowing down nicotine dependence [15, 16]. In
fact, a slow nicotine metabolizer, such as CYP2A6*4A, has
a deleted allele of CYP2A6, which does not metabolize
nicotine. It disrupts the normal digestion process of nicotine,
which is simply evacuated instead. Consequently, slow
metabolizers have potential health benefits in nicotine
dependence treatment for carriers [13, 16–20], acting as
a type of nicotine-dependence treatment drug because the
pharmacologic nicotine dependence treatment strategy
consists of injecting small doses of nicotine into the blood,
which limits the volume of nicotine needed to excite the
brain [7, 21, 22].
3. Limitations of Current
Nicotine-Dependence Therapies
Smoking cessation has major health benefits for men and
women of all ages. However, a long-term cure for nicotine
dependence remains difficult to achieve since more than 80%
of moderate-to-heavy smokers who seek treatment relapse
within 1 year [23]. Although many methods have been
developed to aid smoking cessation (e.g., pharmacother-
apy and behavioral counseling), currently available nicotine
dependence treatments are still rather limited in efficacy [23].
While smoking behavior is sustained biologically by candi-
date nicotine genes, such as the normal nicotine metabolizer
CYP2A6 as well as other candidate nicotine genes, including
dopamine receptors and CYP2B6 gene variants [24, 25],
information about these genes is not used in current nicotine
dependence treatment.
There is a specific mass (1.0–1.5mg) of nicotine that
should be metabolized continuously while smoking in order
to allow the tobacco user to enjoy a pleasurable feeling (trig-
gered by the impact that nicotine has on the brain), which
leads to his/her addiction [26, 27]. According to Hukkanen
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Table 1: Example of CYP2A6 gene variants structures and related enzymatic activities in nicotine metabolism.
CYP2A6 gene variants Nucleotide change Protein alteration Enzymatic activities
CYP2A*1A (wild type) None None Normal
CYP2A6*1H -745A>G Disruption of CCAAT box Decrease
CYP2A6*4A CYP2A6 deleted No produced protein None
CYP2A6*9A -1013A>G, -48T>G; 51G>A Change in TATA box Decrease
CYP2A6*12A Change Exon 3–8 of CYP2A6 origin 10 amino acid substitution Decrease
Note: change in the nucleotide of these gene variants alters or inhibits their enzymatic activities decreasing their nicotine metabolism activities in comparison
with CYP2A6*1A (wild type) gene variants [22].
et al. [22], 1.0–1.5mg of nicotine is readily absorbed while
smoking and easily passes through the lung alveolimembrane
because nicotine is a weak base with a pKa = 0.8.The absorp-
tion of nicotine through the lung membrane is facilitated
by the pH level, and then nicotine is transported by the
bloodstream to the brain within 10 seconds, where it induces
pleasurable sensations. The mechanism of nicotine digestion
occurs with the mediation of multiple candidate nicotine
genes, but the most relevant nicotine gene metabolizers (and
the most well-studied) are the polymorphic alleles of the
CYP2A6 gene.
The role of CYP2A6 polymorphism is a determinant in
the development of nicotine dependence and its treatment
[4]. In treatment, a relapse of the nicotine addiction mecha-
nism occurs because nicotine abstinence reduces dopamine
release, triggering nicotine withdrawal symptoms, such as
unpleasant mood states (irritability, anxiety, depression, and
restlessness), poor concentration, hunger, sleep disturbance,
and a craving for nicotine [28]. These withdrawal symp-
toms often defy the efficacy of current pharmacotherapies
that use bupropion, nortriptyline, clonidine and nicotine
patches, nicotine gum, inhalers, lozenges, and nasal sprays
[29]. The relapse mechanism enhances the capabilities of
the nicotine gene receptors and catalyzers, which act as
powerful biological stimulants, thereby increasing the habit
of smoking. Consequently, actual nicotine therapies only
providemoderate relief. Approximately 80% of patients using
one of these medications return to smoking within the first
year [29]. Although these pharmacologic treatments may
help an individual achieve a relatively long-term abstinence
from nicotine use when combined with behavioral interven-
tions, they are limited because they are not tailored to an
individual’s specific genetic makeup [30].
4. CYP2A6 Polymorphism’s Impact on
Nicotine Dependence
Among the currently identified nicotine gene candidates, the
CYP2A6 gene is the most studied and has been found to
be principally responsible for nicotine metabolism, uptake,
distribution, and clearance [19]. The CYP2A6 gene is located
on the long arm of chromosome 19 [31]. CYP2A6 belongs
to the family of genes known as cytochrome P450, which
has a mixed-function oxidase system and is involved in the
metabolism of xenobiotics in the body. CYP2A6 variants
have properties that induce or inhibit nicotine according to
their structural function [32]; thus, they are hypothesized to
enhance or alter nicotine dependence treatment [3].
The evaluation of the enzymatic activities of CYP2A6 in
in vitro and in vivo experiments has shown that CYP2A6
polymorphisms can alter or enhance the pharmacokinetics
of nicotine according to their structure (deleted/decreased or
full function), thus confirming their propensity to predispose
to or protect individuals from nicotine dependence [19].
Kubota et al. [2] found that the normal nicotine metabolizer
CYP2A6*1A gene variant, which has fully functional alleles,
encodes the enzyme that metabolizes 100% the volume of
inhaled nicotine. Consequently, the CYP2A6*1A alleles are
associated with a higher daily nicotine intake, indicating
that they make the carrier highly susceptible to developing
smoking behavior [5].
In an in vivo study, Benowitz et al. [33] administered
nicotine to clinical trial participants and found that those
who carried fully functioning alleles of CYP2A6*1A secreted
a small quantity of excreted, unchanged nicotine and cotinine
N-glucuronide. This quantity represented 25%–30% of the
excreted urinarymetabolites.They also found a high quantity
of cotinine-derived metabolites, consisting of 58%–67% of
the excreted urinary metabolites. That experiment provides
clues that subjects carrying CYP2A6*1A normal nicotine
metabolizers are highly susceptible to nicotine dependence.
On the other hand, the CYP2A6*2A variant is a deleted
allele of CYP2A6 gene, and it does not produce enzymes
[5]. Therefore, it is inactive and cannot metabolize nicotine
[34, 35]. As a result, carriers of CYP2A6*2A are poor nicotine
metabolizers, smoke less, and recover quickly following
nicotine dependence treatment.
In in vitro studies, participant carriers of the homozygous
CYP2A6 deleted alleles (CYP2A6*4) received nicotine [36].
After two hours, they were found to have very low plasma-
cotinine levels and high levels of unchanged nicotine. These
different enzymatic activities of the CYP2A6 polymorphisms
result from structural change at the nucleotide level in each
of the alleles of CYP2A6, as depicted in Table 1. For example,
CYP2A6*1A is a wild-type allele of CYP2A6, which did
not evolve; on the other hand, CYP2A6*1H to CYP2A6*12
underwent an evolution or mutation expressed by a change
in their nucleotides, thereby affecting their level of enzymatic
activities.
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Table 2: Estimates of CYP2A6 gene variants nicotine metabolizer activities.
Metabolizer groups Estimates enzymatic activities Genotype descriptions
Normal metabolizer (NM) 100% nicotine metabolism No loss of alleles function detectedCYP2A6*1A
Slow metabolizers (SM) (1) Less than 50% of nicotine metabolism activities Less than 1/0 allele loss-of-function.Examples: CYP2A*2 & *4
(2) Nearly 75% of nicotine metabolism activities 1 allele loss-of-functionExamples: CYP2A*9 & *12
Note. In general, gene variant decreases enzymatic activities due to their loss-of-functions [3, 22].
5. CYP2A6 Polymorphism Enzymatic
Activities and Smoking Behavior
In fact, CYP2A6 polymorphism consists of alleles (i.e.,
CYP2A6*2A and CP2A6*4A) that have a complete loss-
of-function or have an enzymatic activity less than 50%,
alleles (i.e., CYP2A6*9A and CYP2A6*12A) with a decrease
of function having enzymatic activity less than 75%, and
alleles (i.e., CYP2A6*1A wild type) that are fully functional
with 100% enzymatic activity [26, 33]. The correlation of
CYP2A6 alleles’ enzymatic activities with the rate of their
markers of 3HC/COT production has led to a method to
determine smokers’ phenotype [37]. Thus, different CYP2A6
allele enzymatic activities have permitted researchers to
classify individual smokers into three CYP2A6 phenotype
groups: slow nicotine metabolizers (people who smoke less),
intermediary nicotine metabolizers (moderate smokers),
and normal metabolizers (heavy smokers) [37], showing
an extreme interindividual variability in smoking behavior.
Table 2 summarizes the classification of CYP2A6 polymor-
phism according to the patients’ enzymatic activities in the
two groups.
6. CYP2A6 Polymorphism Impact on
Nicotine Dependence Treatment
CYP2A6 polymorphism enzymatic activities have been cor-
related with nicotine dependence, but their activities also
influence the nicotine dependence treatment outcome [33].
In clinical trials, individuals who carried CYP2A6 variants
with diminished enzymatic function activity rates and a low
3HC/COT production ratio while taking bupropion/nicotine
replacement therapy (NRT) had the highest cessation rates:
32% compared with those with normal CYP2A6 allele activ-
ities and a high 3HC/COT production ratio, who had only a
10% cessation rate at the end of a 6-month treatment [36].
Using data generated by three clinical trials among Cau-
casian populations, Patterson et al. [38] demonstrated that
individuals using transdermal nicotine patch treatment with
a low 3HC/COT ratio and slow CYP2A6 variant nicotine-
metabolism activity were significantly more likely to quit
smoking than those with high 3HC/COT ratios (indicative
of normal CYP2A6 nicotine-metabolism activities) at week
eight end-of-treatment (46% as opposed to 28%) and 6
month follow-up visits (30% as opposed to 11%).Therefore, it
may be beneficial to translate relevant functions of CYP2A6
polymorphisms into clinical practice, as they variably convert
nicotine to cotinine at 78%, which is further transformed into
trans-3-hydroxycotinine (3HC) [39]. CYP2A6 gene variant
functions may be harnessed to tailor nicotine dependence
treatment for individual treatment needs and should not be
neglected in the case of nicotine dependence.
7. Nicotine Dependence Treatment
One-Size-Fits-All Paradigm
Currently, many new advanced technologies are allowing
researchers to understand more complex interactions among
genes and genetic interactions with environmental agents
[40, 41] and to translate their findings into clinical treatment.
In addition, the emerging sciences of pharmacogenetic and
pharmacogenomic research have revealed gene functions and
the mechanism of their potential clinical utility and validity,
which are being incorporated into drug making and disease
treatment management [42].
Unfortunately, nicotine dependence treatment programs
(cognitive behavioral therapy and pharmacologic therapy)
have been rooted in a “one-size-fits-all” paradigm and cannot
be readily tailored to the unique needs of individual patients
based on their unique constellation of behavioral, biological,
and clinical characteristics [43]. Munafo` et al. [44] proposed
that the one possibility to increase and enhance treatment of
nicotine dependence is to offer nicotine dependence treat-
ments tailored to an individual’s genotype. Since 70%–80%
of inhaled nicotine is biologically converted into cotinine
and 90% of this reaction occurs under the influence of
the enzyme cytochrome P450 2A6 (CYP2A6), the cotinine
is then completely transformed by CYP2A6 into trans-3-
hydroxycotinin [22].
8. Context of Individualized Nicotine
Dependence Treatment
Twin studies have demonstrated that a person’s genetic
makeup contributing to his or her liability to nicotine,
alcohol, and other drug addictions can also shield the indi-
vidual from the development of addiction [38, 41].Therefore,
treating nicotine patients on an individual basis according
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Figure 2: Schema illustrating personalizedmedicine concept and its difficulties.Note.Dashed lines indicate difficulties achieving personalized
medicine. The figure is the illustration of classic “one-size-fits-all” pharmacological therapies to individualized treatment which takes to
account the individual genotype makeup.
to their genotype may help increase a successful nicotine
dependence treatment outcome [41]. For example CYP2A6
polymorphism provides information that governs the basics
if biological and physiological activities in nicotine depen-
dence that can be correlated to individual genetic makeups
[38]. In addition, the human genome shows that the DNA
sequences of any two individuals are 99.9% identical and the
0.1% difference in DNA constitutes the origin of profound
genetic material diversity. Therefore, it is very important that
nicotine addiction treatment be individualized according to
the patient’s genetic makeup [38] as summarized in Figure 2
illustrating personalized medicine concept.
A large interindividual variability of nicotine metabolism
underlines that the treatment of nicotine dependence should
consider information regarding candidate nicotine genes.
In a quantitative study, Nakajima et al. [35] compared
different alleles ofCYP2A6 genes’ nicotine-metabolism activ-
ities and found large interindividual variability in the coti-
nine/nicotine ratios in races with the following means:
Caucasian 7.1 ± 4.7; Black 7.2 ± 5.0; Chinese, 8.7 ± 11.9;
and Japanese, 3.8 ± 3.1. These different nicotine metabolism
activities of CYP2A6 alleles in races confirmed the varying
prevalence of nicotine dependence across a race spectrum
[18, 22, 45].
9. Finding the Impact of
CYP2A6 Polymorphisms
To date, few emerging smoking-cessation clinical trials have
reported that CYP2A6 activity is associated with nicotine-
quitting success [30]. Unraveling the role of gene variants and
determining how to use them to design effective therapy are
difficult [46] but not unachievable [40].
This goal can be realized through studies that may
provide accurate assessment through multivariable analyses
ofCYP2A6 genes variants in correlationwith nicotine depen-
dence and withdrawal syndrome, other genes, and different
forms of therapies [42]. A correlational study could also help
examine towhat extentCYP2A6major variants are correlated
with other nicotine dependence risk factors and how they can
influence nicotine dependence treatment.
10. Summary
CYP2A6 polymorphismsmediate themetabolism of nicotine
according to their ability to encode for the enzyme catalyzer
of nicotine to cotinine [13].They serve as a biological gateway
for nicotine to reach the brain by the bloodstream [13].
The fully functional allele CYP2A6*1A metabolizes enough
nicotine each time a tobacco user inhales the smoke of
cigarette to lead to nicotine dependence. In contrast, slow
nicotine metabolizers catalyze less nicotine, which prevents
addiction [22]. In nicotine dependence treatment, carriers of
slow nicotine metabolizer genes are 1.7 times more likely to
quit smoking or maintain abstinence than those who have
a normal nicotine metabolizer underlining their potential
health benefit; these metabolizers can therefore be used in
nicotine dependence treatment [30].
The role of CYP2A6 polymorphism capability to cat-
alyze nicotine provides clues that nicotine treatment should
be individualized. Twin, adoption, clinical trial, and case-
control studies suggested that there is strong evidence of
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the influence of genetic variants in nicotine-dependence
etiology and treatment, where genetic variants’ contributions
were evaluated at more than 50% [1, 32], conveying the
possibility that CYP2A6 polymorphism information analysis
may strengthen nicotine dependence treatment.
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